This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Gastric ulcer - GU :treatment if H.pylori +ve

Authoring team

  • H.pylori eradication therapy as for duodenal ulcer followed by antisecretory therapy for two months
    • the reason for this latter recommendation is the lack of evidence that gastric ulcers heal as quickly as DU after H.pylori eradication alone
    • long term treatment with a PPI or misoprostol should be considered in patients with proven ulcer who continue to take NSAIDs
  • no known single best eradication regime
    • One week Triple Therapy - First Line (no continued antisecretory required) PPI (standard dose twice daily) or RBC (ranitidine bismuth citrate), plus Amoxycillin 500 - 1g twice daily or Metronidazole 400-500mg twice daily,plus Clarithromycin 500mg twice daily
    • it is sensible to avoid metronidazole if the patient has had a previous course of treatment with this agent
    • One week Quadruple Therapy - Second line: PPI (standard dose twice daily), plus Bismuth Subcitrate 120mg qds), plus metronidazole 400-500mg tds, plus tetracycline 500mg qds
    • compliance with treatment has been shown to be very important in determining the success of triple therapy

Reference:

  1. BSG (2002). Dyspepsia management guidelines.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.